Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics

Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics

Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.

Learning Objectives

  • Pulmonary arterial hypertension as a clinical condition
  • Applying proteomics to risk stratification
  • Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition

Christopher Rhodes, MA, Cantab, PhD

Christopher Rhodes, MA, Cantab, PhD

Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London

Martin R. Wilkins

Martin R. Wilkins

Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London

Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics

A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins

Share with colleagues

More webinars

WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure 

Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.

Learn more

WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn more

WebinarProteomics for precision neuroscience: The power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

Explore webinars in our interactive viewer